ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
Telix Announces a Final Patient Dosed and Recruitment Completed into the Phase III Pivotal ZIRCON Study of TLX250-CDx for Kidney Cancer Imaging
Chief Medical Officer, Dr. Colin Hayward, Discussion with Wilsons Advisory
Telix Chief Medical Officer, Dr. Colin Hayward, was hosted this week by Shane Storey, Senior Research Analyst at Wilsons Advisory and Stockbroking Limited, to discuss R&D insights across Telix’s imaging and therapeutic research pipeline.
Telix AGM 2022
Telix's 2022 AGM was held on Wednesday, 18th May 2022 at The Events Centre in Melbourne, Australia.
Telix Further Strengthens European Distribution Network for Illuccix
Telix announces agreements with Avanço and THP for the distribution of Telix’s prostate cancer investigational imaging product for the Portuguese and Austrian, Czech Republic and Slovak Republic markets.
Activities Report and Appendix 4C for March 2022 Quarter
Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March 2022
First Patients Dosed with Illuccix® – Telix’s Approved Prostate Cancer Imaging Agent
Telix announces the first commercial doses of its prostate cancer imaging agent, Illuccix®
Notice of Annual General Meeting 2022
Telix provides notice of The Annual General Meeting of Shareholders on Wednesday 18 May 2022
Telix Announces Licence Agreement with Lilly for Olaratumab
Telix announces a licence agreement for Lilly’s olaratumab antibody, for diagnosis and treatment of human cancers.
PSMA-PET Imaging to be Funded through Medicare in Australia from July
Telix welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for patients with prostate cancer on the Medicare Benefits Schedule (MBS) from 1 July 2022.
Telix, GMS and Monash Awarded $23M Federal Government Funding as part of $71M Australian Precision Medicine Enterprise (APME) Project
Telix announces that it is part of a $71.2 million Australian Precision Medicine Enterprise Project, which has been awarded $23 million in Federal Government funding